SCHEDULE: Addex Therapeutics CEO's Stake Update

Timothy Mark Dyer, CEO of Addex Therapeutics, has updated his beneficial ownership filing, now holding approximately 8.89% of the company's shares following recent share dilution.

Summary

• This filing is an amendment (Amendment No. 9) to a Schedule 13D, updating the beneficial ownership of Timothy Mark Dyer, CEO and Board Member of Addex Therapeutics Ltd.
• The update is primarily due to dilution from the company's additional share sales, causing Dyer's ownership percentage to decrease.
• As of August 26, 2026, Timothy Mark Dyer beneficially owns 19,095,510 shares, representing approximately 8.89% of the Issuer's shares.
• This total includes 16,848,979 ordinary shares and 2,246,531 shares issuable upon exercise of options exercisable within 60 days of August 26, 2026.
• The percentage ownership is based on 210,292,217 ordinary shares outstanding as of August 26, 2026.
• Dyer acquired shares through various means including founding shares, private placements, compensation for his CEO services, and exercise of stock options.
• The filing states that Dyer reserves the right to change his plans at any time based on various factors including business objectives, financial condition, and market conditions.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting an update on beneficial ownership due to share dilution rather than a significant change in strategy or performance. The CEO's substantial stake and continued involvement are positive indicators, but the lack of new strategic information tempers a more enthusiastic outlook.

Positives

• Timothy Mark Dyer, the CEO, continues to hold a significant stake in Addex Therapeutics, demonstrating ongoing commitment.
• The CEO's beneficial ownership includes a substantial number of shares (19,095,510) and exercisable options, indicating a strong alignment of interests.
• The filing details a long history of share acquisition and option grants, reflecting sustained engagement with the company since its founding.

Negatives

• The primary reason for the filing is dilution, indicating that the company has issued additional shares, reducing the ownership percentage of existing shareholders.
• The filing does not contain new strategic information or performance updates, serving mainly as an administrative update on ownership.

Risks

• The company has experienced dilution from additional share sales, which can negatively impact the ownership percentage of existing shareholders.
• The CEO reserves the right to change his plans at any time, introducing potential uncertainty regarding future actions or strategic shifts.

Future Outlook

The filing indicates that Timothy Mark Dyer reserves the right to change his plans at any time based on his ongoing evaluation of business and liquidity objectives, the Issuer's financial condition, business, operations, competitive position, prospects and/or Share price, industry, economic and/or securities markets conditions, alternative investment opportunities, and other relevant factors.

Management Comments

• The reporting person reserves the right to change its plans at any time, as it deems appropriate, in light of its ongoing evaluation of (i) its business and liquidity objectives? (ii) the Issuer's financial condition, business, operations, competitive position, prospects and/or Share price? (iii) industry, economic and/or securities markets conditions? (iv) alternative investment opportunities? and (v) other relevant factors.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are common for significant beneficial owners, especially insiders like CEOs, to report changes in their holdings. This particular filing highlights the impact of ongoing capital-raising or share issuance activities on ownership percentages, a common theme in the biotechnology and pharmaceutical sectors where companies often require continuous funding for research and development.

Stakeholder Impact

• Shareholders: Dilution from additional share sales may reduce their proportional ownership and voting power.
• Management: The CEO's continued significant stake reinforces his commitment and alignment with shareholder interests.

Next Steps

• Timothy Mark Dyer will continue to evaluate his investment and strategic position in Addex Therapeutics.
• Future actions by Timothy Mark Dyer are subject to his ongoing assessment of market conditions, company performance, and alternative investment opportunities.

Key Dates

Keywords

Addex Therapeutics, Schedule 13D, Beneficial Ownership, Timothy Mark Dyer, CEO, Share Dilution, Stock Options, Ordinary Shares